ArticleNanomedicine (London, England)2008
Co-delivery of siRNA and an anticancer drug for treatment of multidrug-resistant cancer.
Article in Nanomedicine (London, England), 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 117 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
117 citing papers in PubMed, 365 citations in OpenAlex.
- Rational design of anticancer multidrug nanosystems and their adaptation for glioblastoma treatment.Drug delivery and translational research · 2026Review
- Breakthroughs in the nanoparticle-mediated delivery of siRNA for breast cancer treatment.Nanomedicine (London, England) · 2025Review
- Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.Pharmaceutics · 2025Review
- Design, development, and preclinical evaluation of pirfenidone-loaded nanostructured lipid carriers for pulmonary delivery.Scientific reports · 2025Article
- siRNA as a criterion in host immunity and cancer immunotherapy: modulating factors and nano-conjugate based approach for intervention.International journal of biological sciences · 2025Review
- Nanoparticle targeting strategies for traumatic brain injury.Journal of neural engineering · 2024Review
- Personalized Versus Precision Nanomedicine for Treatment of Ovarian Cancer.Small (Weinheim an der Bergstrasse, Germany) · 2024Article
- The Role of Inhaled Chitosan-Based Nanoparticles in Lung Cancer Therapy.Pharmaceutics · 2024Review
- Nanotechnology-Based Strategy for Enhancing Therapeutic Efficacy in Pancreatic Cancer: Receptor-Targeted Drug Delivery by Somatostatin Analog.International journal of molecular sciences · 2024Article
- Review
- Transitional Insight into the RNA-Based Oligonucleotides in Cancer Treatment.Applied biochemistry and biotechnology · 2024Review
- The advancement of siRNA-based nanomedicine for tumor therapy.Nanomedicine (London, England) · 2024Review
- Nanodelivery systems: An efficient and target-specific approach for drug-resistant cancers.Cancer medicine · 2023Review
- Emergence of Nanoscale Drug Carriers through Supramolecular Self-Assembly of RNA with Calixarene.International journal of molecular sciences · 2023Article
- Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications.Pharmaceutics · 2023Review
- Nano-Enabled Strategies for the Treatment of Lung Cancer: Potential Bottlenecks and Future Perspectives.Biomedicines · 2023Review
- Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges.Pharmaceutics · 2023Review
- Advanced strategies for nucleic acids and small-molecular drugs in combined anticancer therapy.International journal of biological sciences · 2023Review
- Emerging nanotechnology-based therapeutics to combat multidrug-resistant cancer.Journal of nanobiotechnology · 2022Review
- Encapsulation of miRNA and siRNA into Nanomaterials for Cancer Therapeutics.Pharmaceutics · 2022Review
57 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
aimsTo develop a novel nanomedicine approach for the treatment of multidrug-resistant (MDR) cancer by combining an anticancer drug and suppressors of cellular resistance within one multifunctional nanocarrier-based delivery system (NDS). MATERIALS &
methodsThe NDS consisted of cationic liposomes (carrier, 100-140 nm), doxorubicin (DOX, anticancer drug), siRNA targeted to MRP1 and BCL2 mRNA (suppressors of pump and nonpump cellular-resistance, respectively). The resulting approximately 500 nm complex has a zeta potential of +4 mV. RESULTS & DISCUSSION: The NDS provides an effective co-delivery of DOX and siRNA as well as cell-death induction and suppression of cellular resistance in MDR lung cancer cells.
conclusionWe demonstrate NDS-enhanced efficiency of chemotherapy to a level that cannot be achieved by applying its components separately.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.